A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
This study investigates the effectiveness and safety of 12 weeks of treatment with
 JNJ-16269110 (R256918), in overweight and obese patients. The primary measure of
 effectiveness is the change in body weight at a clinically relevant dosage level during
 treatment. Additional measures include body mass index (BMI), DEXA (dual X-ray absorptiometry
 which is a specialized x-ray test that measures body composition), fasting glucose, lipid
 levels, and blood pressure. Safety assessments performed during the trial include laboratory
 tests, vital sign measurements, and adverse event reporting.
This is a randomized (assigned study drug by chance), double-blind (both the patient and
 investigator do not know whether patient is assigned to receive study drug or placebo),
 placebo-controlled study involving overweight and obese patients. Patients are randomized to
 one of 4 treatment groups and receive study drug or placebo for a period of 12 weeks. The
 study consists of 3 phases: a pretreatment phase (including a screening period of 1 week and
 a period prior to active treatment of 4 weeks), the treatment period of 12 weeks, and a
 posttreatment phase (consisting of a follow-up visit). Standardized nonpharmacologic therapy
 (individualized calorie deficit diets containing no more than 30% calories from fat and
 nutritional counseling) will be administered from Week 4 through the follow-up period. During
 the treatment period, patients visit the center every two weeks. On each visit, patients come
 to the clinic after 8 hours fasting. For effectiveness assessments, patients will be weighed
 and BMI calculated at each visit; waist and hip circumference and DEXA measurements (for body
 composition and fat mass analysis) will be performed at selected time points. Additional
 effectiveness assessments from a blood sample include levels of fasting hemoglobin type A1c
 (HbA1c), glucose, cholesterol, triglycerides, insulin, C-peptide, and gastrointestinal
 hormones. Insulin sensitivity and pancreas function are evaluated. Safety evaluations,
 including incidence of adverse events, clinical laboratory results, vital signs, and
 electrocardiograms, are performed during the study. Patients complete a questionnaire related
 to stomach/bowel symptoms (GI) throughout the study. Blood samples will also be drawn for an
 analysis of the subjects genes and an analyses of the body's handling of the study drug. The
 overall duration of the study for each patient is approximately 19 weeks. The study
 hypothesis is that treatment with JNJ-16269110 (R256918) will cause a change in body weight
 compared to placebo and will be well tolerated in overweight and obese patients. This
 hypothesis will be investigated at each dosage level to determine a clinically relevant dose.
 5 mg capsules, 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.
Inclusion Criteria:

 -  Obese or overweight at screening defined as: BMI greater than or equal to 30 kg/m2 and
 <50 kg/m2 or BMI greater than or equal to 27 kg/m2 and <50 kg/m2 in the presence of
 controlled hypertension and/or treated or untreated dyslipidemia. For patients
 receiving antihypertensive and/or hypolipidemic medications, these should have been at
 a stable dosage for at least 2 months before the start of the run-in period.
 Controlled hypertension is defined as a diastolic blood pressure <100 mmHg and a
 systolic blood pressure <160 mmHg, in the presence of antihypertensive drug treatment.
 For patients who are not on lipid-lowering drugs, dyslipidemia is defined as LDL-C
 greater than or equal to 3.4 mmol/L (130 mg/dL), HDL C <1 mmol/L (40 mg/dL) for men or
 <1.3 mmol/L (50 mg/dL) for women, or triglycerides greater than or equal to 1.7 mmol/L
 (150 mg/dL)

 -  A stable weight, i.e., increasing or decreasing not more than 5 kg in the 3 months
 before the start of the run-in period

 -  Consumption of breakfast and dinner on a daily basis

 -  Ability to swallow the intact capsule (17.5 mm in length and 9.1 mm in diameter) with
 water, as judged by e.g., the patients's history of having no difficulty with
 swallowing e.g., capsules or intact tablets

 -  Fasting plasma glucose <7.0 mmol/L (126 mg/dL) at screening

 -  Women must be postmenopausal or surgically incapable of childbearing or if sexually
 active, be practicing an effective method of birth control

 Exclusion Criteria:

 -  History of obesity with a known cause (e.g., Cushing's disease)

 -  History of anorexia nervosa, bulimia, or binge-eating disorder

 -  An established diagnosis of diabetes mellitus or treatment with glucose lowering
 prescription drugs at screening

 -  Prior exposure or known contraindication or hypersensitivity to R256918

 -  History of weight-reducing diet or receiving any drugs to treat obesity within the 3
 months prior to screening

 -  Treatment with any investigational drug or device within 1 month before the start of
 the run-in period

 -  History or evidence of liver or renal impairment

 -  History of HIV or presence of hepatitis C antibodies or positive hepatitis B serology

 -  History of clinically significant gastro-intestinal disease

 -  History of major gastro-intestinal surgery other than appendectomy or uncomplicated
 cholecystectomy

 -  Previous gastric restrictive surgery or other surgical procedures to induce weight
 loss

 -  Liposuction within the last 3 months before screening

 -  Pregnant or nursing women, or women who plan to become pregnant during the study

 -  History of significant cardiovascular disease or hypertension

 -  Elevated levels of thyroid-stimulating hormone (TSH)

 -  A significant change in smoking habits within 3 months of the start of the run-in
 period

 -  Malignancy or a history of a malignancy within 5 years before the start of the run-in
 period, other than basal cell carcinomas of the skin or in situ cervical carcinoma

 -  History of seizures or significant central nervous system-related disorders

 -  History of significant psychiatric disorder, including, schizophrenia, or psychosis